Table 1.
Overview of studies on cTACE and DEB-TACE.
| Table 452. | Patient Number | Overall Survival (Months) | Progression-Free Survival (Months) | Reference |
|---|---|---|---|---|
| cTACE | ||||
| palliative and neoadjuvant | 452 | 12.6 (palliative) 25.8 (neoadjuvant) |
5.9 (palliative) 10.8 (neoadjuvant) |
[32] |
| cTACE after FOLFOX failure | 24 | 21.1 | 8.8 | [33] |
| palliative | 21 | 13.8 | 5.8 | [34] |
| palliative | 21 | 7.7 | [35] | |
| palliative | 121 | 9 | 5 | [36] |
| DEBIRI-TACE | ||||
| efficacy | 55 | 19 | 11 | [39] |
| palliative/safety | 82 | 25 | 8 | [40] |
| palliative/safety | 27 | 5.4 | [41] | |
| efficacy and safety | 30 (17 TACE vs. 13 TACE and bevacizumab) | 5.8 TACE vs. 12 TACE and bevacizumab | 4 TACE vs. 6 TACE and bevacizumab | [43] |
| efficacy | 57 | 37.4 | 10.8 | [44] |
| efficacy | 74 | 22 (DEBIRI-group) | 7 (DEBIRI-group) | [42] |
| efficacy | 70 | 15.3 (DEBIRI and FOLFOX/bevacizumab) | [45] | |
| neoadjuvant | 40 | 50.9 | [46] |